Attendee search 

Luye Pharma Group Co., Ltd. is a professional pharmaceutical enterprise built on a solid foundation of research and development and focusing on the largest and fastest growing therapeutic areas - central nervous system, oncology, cardiovascular system, and metabolism . The company was founded in 1994 and listed on the main board of the Hong Kong Stock Exchange in 2014 (02186.HK). The company has state-of-the-art production facilities located in Yantai, Nanjing, Beijing and Luzhou; as well as overseas branch offices in EU, United States, Singapore and Malaysia. The company has approximately 4,000 employees, including close to 300 R&D specialists and over 1,300 sales and marketing personnel. Luye Pharma is devoted to providing customers with high-quality innovative pharmaceutical products and professional services. The company currently sells approximately 30 products and over 80% of its total revenue is attributable to patent-protected products. Luye Pharma has an extensive sales & distribution network covering over 11,000 hospitals in 30 provinces, autonomous regions and municipalities in China, as well as exporting to many overseas countries and regions. Luye Pharma currently has 8 product candidates for overseas markets: one is preparing to submit NDA application; three are undergoing clinical trials in the US and one will start clinical trials in the US. soon.

In addition, Luye has its own biosimilar business (novel antibodies, prolia, xgeva, eylea, avastin, opdivo, trulicity, consentyx, zaltrap, CAR-T); Established in 2013, Boan Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic antibodies, which are mainly focused on key therapeutic areas such as oncology, diabetes and immunological diseases.

R&D attributed company

A clinical stage company

CICCB is an investment company, cofounded by China International Capital Corporation Limited (‘CICC’) and CCB Trust Co., Ltd. CICC is the No.1 investment bank in China which was founded in 1995 as a joint venture of China Construction Bank and Morgan Stanley. And CCB trust is the No.1 trust in China, with AUM more than 250 bn USD. In addition, CCB trust is the wholly owned subsidiary of China Construction Bank, one of Top 4 state owned banks in China. Our main business covers asset management, IPO, M&A and strategic investment for industry. Leveraged by shareholders' strong resource, CICCB's investment areas cover full value chain, including VC, PE, pre-IPO and other stages. Target industries include healthcare, TMT, consumer-related and other emerging strategic industries. As a strategic integration platform for CICC and CCB, CICCB is committed to becoming an all-round asset management institution with global influence in key areas.

Pfizer Inc. is an American multinational pharmaceutical corporation. One of the world's largest pharmaceutical companies.

foucusing on precision medicine.,biotechnology and digital medicine.

focus on CVD, oncology，immunology

Company Description

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.